Program
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5
In Sino Biopharmaceutical’s pipeline, 41BBcondi/CEACAM5双抗
. Its studies are led by Sino Biopharmaceutical.
Furthest: phase 2, since Dec 4, 20232 company-led studies, 2 open or runningNext primary completion: May 21, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 22 open or running | phase 2since Dec 4, 2023 | Dec 4, 2023 | May 21, 2028phase 2 · NCT07387081 |
- Named in Sino Biopharmaceutical’s own pipeline as
LM-24C5
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 4, 2023First study: phase 2 study in Advanced Solid TumorFirst studyNCT06187402 · 49 planned · United States
- Dec 2, 2025Phase 2 study in Advanced Solid Tumor CancerNCT07387081 · 130 planned · China
Ahead
- May 21, 2028Primary completion: phase 2 study in Advanced Solid Tumor CancerNCT07387081
TargetBeta
“41BBcondi/CEACAM5双抗”the company's pipeline, read by Claude · source
“A bispecific antibody targeting both the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07387081Advanced Solid Tumor Cancer · China | 2 | Recruiting | May 21, 2028 | 130 |
| NCT06187402Advanced Solid Tumor · United States | 2 | Recruiting | Jun 30, 2026 | 49 |
How it is read
Names in the registry
- “LM-24C5”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.